Risk of PAH in CHD

Delay in PAH diagnosis

Importance of
regular screening

Screening for PAH

PAH diagnostic algorithm

Foundational
pathways in PAH

Resources and
support

For U.S. Healthcare Professionals

Risk of PAH in CHD

Delay in PAH diagnosis

Importance of regular screening

Screening for PAH

PAH diagnostic algorithm

Foundational pathways in PAH

Resources and support

Risk of PAH in CHD

Delay in PAH diagnosis

Importance of
regular screening

Screening for PAH

PAH diagnostic algorithm

Foundational
pathways in PAH

Resources and
support

Trees and other plant life

Site Map

Home
Risk of PAH in CHD
Delay in PAH diagnosis
Importance of regular screening
Screening for PAH
PAH diagnostic algorithm
Foundational pathways in PAH
Resources and support

CHD=congenital heart defect/disease; PAH=pulmonary arterial hypertension.

This site is published by Actelion Pharmaceuticals US, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Actelion Pharmaceuticals US, Inc., recognizes that the internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country.

Third party trademarks used herein are trademarks of their respective owners.

Last updated October 2024 | cp‍-‍306379v3

Contact us Site Map

© Johnson & Johnson and its affiliates 2024

Privacy policy Legal notice Cookie policy Cookie settings Do not sell or share my personal information